Moreover, targeting MCJ to inhibit legumain secretion or enhance the clearance of reactive oxygen species (ROS) presents promising therapeutic strategies for the management of metastatic ccRCC. Here, DNAJC15 is linked to nonpapillary renal cell carcinoma.